The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Response to treatment with denosumab in patients with giant cell tumor of bone (GCTB): FDG PET results from two phase 2 trials.
Keith M. Skubitz
Consultant or Advisory Role - Amgen; ARIAD/Merck; Johnson & Johnson; Novartis; Pfizer/Schering-Plough; Systems Medicine
Stock Ownership - Johnson & Johnson
Research Funding - Amgen; ARIAD/Merck; Celgene; Cell Therapeutics; GlaxoSmithKline; Infinity Pharmaceuticals; Schering-Plough; Systems Medicine
Expert Testimony - Plaintiff in class action on role of bisphosphonates in ONJ (U)
Other Remuneration - Amgen
David Morgan Thomas
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Sant P. Chawla
Consultant or Advisory Role - CytRx Corporation; Merck; PharmaMar; Sanofi
Research Funding - CytRx Corporation; Merck; PharmaMar; Sanofi
Arthur P. Staddon
No relevant relationships to disclose
Jacob Engellau
Consultant or Advisory Role - Amgen
Amy Feng
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Bruce A. Bach
Employment or Leadership Position - Amgen
Stock Ownership - Amgen